论文信息 - Use of recombinant factor VIIa to treat persistent bleeding following dental extractions in two cirrhotic patients

Use of recombinant factor VIIa to treat persistent bleeding following dental extractions in two cirrhotic patients

Background and Objectives A single dose of recombinant factor VIIa (rFVIIa) has been shown to be effective and safe in correcting the prothrombin time (PT) in cirrhotic patients, but no clinical data exists demonstrating its efficacy in arresting active bleeding.

[1] R. Porte,et al. REDUCED TRANSFUSION REQUIREMENTS BY RECOMBINANT FACTOR VIIa IN ORTHOTOPIC LIVER TRANSPLANTATION: A Pilot Study , 2001, Transplantation.

[2] C. Gaillard,et al. Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. , 2000, The American journal of medicine.

[3] C. Baird. The pilot study. , 2000, Orthopedic nursing.

[4] A. Burroughs,et al. Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis. , 1999, Journal of hepatology.

[5] T. Drewniak,et al. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. , 1999, Transplantation proceedings.

[6] E. Toffolon. Correcting PT with factor 7 may not improve clotting. , 1998, Gastroenterology.

[7] K. Reddy,et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. , 1997, Gastroenterology.

[8] V. Ionasescu,et al. Gastrointestinal manifestations of the muscular dystrophies , 1982 .